Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Acute myeloid leukemia (AML) with FLT3-ITD mutations presents a challenge for hematopoietic cell transplantation (HCT) outcomes.
• Maintenance therapy post-HCT is crucial for improving survival in these high-risk patients.

Purpose of the Study:

• To investigate factors influencing the efficacy of post-HCT gilteritinib maintenance therapy in FLT3-ITD mutated AML.
• To explore reasons for regional differences in treatment benefit observed in the BMT CTN 1506 trial.

Main Methods:

• Post-hoc analysis of the phase 3 BMT CTN 1506 trial data.
• Evaluation of time from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and pre-HCT measurable residual disease (MRD).

Main Results:

• Post-HCT gilteritinib showed survival benefit for patients transplanted < 120 days from diagnosis and/or those receiving pre-HCT FLT3 inhibitors.
• Shorter time to HCT and pre-HCT FLT3 inhibitor use were associated with higher pre-HCT MRD levels.
• Geographic variations in transplant timing and FLT3 inhibitor use likely explain regional differences in gilteritinib efficacy.

Conclusions:

• Time to HCT and pre-HCT FLT3 inhibitor use are critical factors impacting MRD and gilteritinib effectiveness.
• Optimizing pre-HCT treatment strategies may mitigate the need for post-HCT maintenance therapy.